Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pegulicianine→

Pegulicianine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2230217-17-9
Molecular formula
C118H151N19O24S4.(C2H4O)n
Molecular weight
Not verified g/mol
Drug class
Optical fluorescence imaging agentprotease-activated peptide-dye conjugate
Mechanism of action
After intravenous administration, proteolytic cleavage in the tumour microenvironment activates the pegulicianine fluorophore. The activated fluorophore emits near-infrared fluorescence when illuminated, enabling intraoperative visualisation of residual cancerous tissue in the lumpectomy cavity.
Indications / reported uses
  • Adjunct fluorescence imaging in adults with breast cancer to assist intraoperative detection of cancerous tissue within the resection cavity after removal of the primary specimen during lumpectomy surgery; used with an approved fluorescence imaging system.

Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7160e774-663a-43e4-ba4a-06cc57830e66&type=display · https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-imaging-drug-assist-detection-cancerous-tissue-following-lumpectomy · https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-lumisight · DailyMed

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pegulicianine Environmental Risk Assessment (ERA) (the Pegulicianine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.